GRTX
- Galera Therapeutics, Inc.
()
Overview
Company Summary
Galera Therapeutics, Inc. (GRTX) is a biopharmaceutical company dedicated to the development of innovative therapies for patients with cancer and other diseases. Specifically, Galera focuses on the development of drugs targeting the biochemical process of oxygen metabolism, known as redox biology.
Redox biology plays a significant role in various diseases, including cancer, fibrosis, and neurodegenerative disorders. Galera's proprietary platform technology aims to address the challenges associated with redox biology and develop therapeutics to modulate this process effectively.
The company's lead product candidate is called avasopasem manganese (GC4419), which is being developed for the prevention of radiation-induced severe oral mucositis in patients with head and neck cancer. Severe oral mucositis is a common and debilitating side effect of radiation therapy that leads to painful ulcers, difficulty in eating and drinking, and an increased risk of infection.
GC4419 works by converting harmful free radicals generated during radiation therapy into non-toxic molecules, protecting healthy tissues from damage. This unique mechanism of action has shown promise in clinical trials, potentially improving the quality of life for cancer patients undergoing radiation therapy.
Galera Therapeutics also explores other potential applications of redox modulating therapies beyond radiation-induced mucositis. Their research and development efforts focus on expanding the use of their technology to other indications, such as idiopathic pulmonary fibrosis, liver diseases, and neurodegenerative disorders.
Overall, Galera Therapeutics is committed to leveraging its expertise in redox biology to develop and commercialize innovative treatments that can make a meaningful difference in patients' lives.